ISG Technologies postponed the release of its year-end financialresults this month, citing a lawsuit filed against the Mississauga,Ontario, PACS developer by its former president and CEO ThomasCafarella. ISG said it needs time to determine whether it
ISG Technologies postponed the release of its year-end financialresults this month, citing a lawsuit filed against the Mississauga,Ontario, PACS developer by its former president and CEO ThomasCafarella. ISG said it needs time to determine whether it shouldtake a charge as a provision for the litigation.
Cafarella filed suit against ISG last month, charging the companywith breach of contract when it dismissed him on Aug. 8 (SCAN8/28/96). Cafarella is claiming damages of $1.5 million (Canadian).
In addition to Cafarella, two other executives associated withthe former Siemens executive have left ISG. They are Denis O'Connor,a Loral veteran who was vice president of sales and marketing,and Gary Hepworth, director of human resources. Both had beenhired by Cafarella, according to ISG's CFO, Gerry McDonald.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.